Business Context and Reporting Period
Company: MDB Capital Holdings, LLC (MDBH)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter and Six Months Ended June 30, 2025
Business Overview: MDB is a holding company operating through two primary segments: (1) Broker Dealer & Intellectual Property Services (Public Ventures and PatentVest) and (2) Technology Development (MDB Minnesota One). Notably, the company deconsolidated its former majority-owned subsidiary, eXoZymes, following its November 2024 IPO; eXoZymes is now accounted for as an equity method investment.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Total Operating Income (Loss) | $(1,072,322) | $1,628,061 |
| Net Loss | $(14,851,390) | $(12,415,192) |
| Net Loss Attributable to MDB | $(14,834,993) | $(11,489,866) |
| Net Loss Per Share (Class A & B) | $(1.49) | $(1.24) |
| Cash and Cash Equivalents | $17,091,584 | $20,437,492 (Dec 31, 2024) |
| Total Assets | $63,517,689 | $71,976,399 (Dec 31, 2024) |
| Total Liabilities | $1,734,255 | $1,903,065 (Dec 31, 2024) |
| Working Capital | $17,739,227 | $24,928,197 (June 30, 2024) |
| Net Cash Used in Operating Activities | $(3,406,093) | $(6,468,895) |
Material Changes vs. Prior Period
- Revenue Decline: Fee income dropped to zero for the three months ended June 30, 2025, compared to $1.3 million in the prior year quarter. For the six-month period, fee income was $2.14 million, an increase of 64.2% year-over-year, driven by investment banking activity in February 2025.
- Investment Losses: The company recorded a significant unrealized loss on investment securities of $3.66 million for the six months ended June 30, 2025, compared to an unrealized gain of $152,276 in the prior year period. This was the primary driver of the operating loss.
- Deconsolidation Impact: Research and Development (R&D) costs were $0 for the six months ended June 30, 2025, a 100% decrease from $514,976 in the prior year, due to the deconsolidation of eXoZymes.
- Equity Method Loss: The company recognized an equity in loss of $1.98 million related to its investment in eXoZymes, which did not exist in the prior year period as eXoZymes was consolidated.
- Expense Reductions: Total operating costs decreased by 16.8% year-over-year to $12.23 million, primarily due to lower compensation and professional fees following the deconsolidation of eXoZymes.
Guidance, Outlook, and Risks
- Management Commentary: Management attributes the increase in net loss primarily to unrealized losses on securities held by the broker-dealer and the equity method loss from eXoZymes. Operating cash burn improved compared to the prior year ($3.4M vs $6.5M used).
- Capital Resources: The company maintains a $2.0 million revolving credit facility (undrawn as of June 30, 2025). Public Ventures (broker-dealer) maintains net capital of $8.6 million, well above the $250,000 regulatory minimum and the $5.0 million DTC membership requirement.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses in internal control over financial reporting. Remediation efforts are ongoing.
- Risk Factors:
- Market Risk: Significant exposure to unrealized losses on investment securities (warrants and common stock).
- Regulatory/Political: Risks associated with potential U.S. tariffs, changes in trade policy, and reductions in federal research grants which could impact partner companies.
- Technology Risk: Uncertainty regarding the commercial viability of technologies developed by partner companies (e.g., M1's pharmaceutical platform).
Investor Verification Checklist
- Investment Portfolio Valuation: Verify the composition and fair value assumptions of the $3.19 million investment securities portfolio, specifically the Level 3 warrants valued using Black-Scholes models with high volatility inputs (~106%).
- Equity Method Investment: Review the financial health of eXoZymes (46.9% ownership) to assess the sustainability of the $1.98 million equity loss recorded in the period.
- Internal Control Remediation: Monitor the progress of remediation for the identified material weaknesses in internal controls over financial reporting.
- Liquidity Runway: Assess the company's ability to fund operations given the $3.4 million cash burn from operations and the lack of significant revenue in the Q2 2025 quarter.
- Related Party Transactions: Review the $928,867 in related party operating expenses paid to entities controlled by principal members.